Expanded carrier screening in reproductive medicine-points to consider: a joint statement of the American College of Medical Genetics and Genomics, American College of Obstetricians and Gynecologists, National Society of Genetic Counselors, Perinatal Quality Foundation, and Society for Maternal-Feta

The Perinatal Quality Foundation and the American College of Medical Genetics and Genomics, in association with the American College of Obstetricians and Gynecologists, the Society for Maternal-Fetal Medicine, and the National Society of Genetic Counselors, have collaborated to provide education for clinicians and laboratories regarding the use of expanded genetic carrier screening in reproductive medicine. This statement does not replace current screening guidelines, which are published by individual organizations to direct the practice of their constituents. As organizations develop practice guidelines for expanded carrier screening, further direction is likely. The current statement demonstrates an approach for health care providers and laboratories who wish to or who are currently offering expanded carrier screening to their patients.

[1]  D. Driscoll,et al.  Fragile X syndrome: Diagnostic and carrier testing , 2005, Genetics in Medicine.

[2]  W. Grody,et al.  American College of Medical Genetics Consensus Statement on Factor V Leiden Mutation Testing , 2001, Genetics in Medicine.

[3]  R. Adams,et al.  The American College of Obstetricians and Gynecologists , 2018, Obstetrics & Gynecology.

[4]  Charles C. Strange,et al.  Expanded carrier screening panels—does bigger mean better? , 2013, Journal of Community Genetics.

[5]  R. Bennett,et al.  Erratum to: Genetic Counseling and Testing for FMR1 Gene Mutations: Practice Guidelines of the National Society of Genetic Counselors , 2012, Journal of Genetic Counseling.

[6]  S Kamen,et al.  The task force. , 1976, Journal of hospital dental practice.

[7]  S. Keiles,et al.  Molecular Testing for Cystic Fibrosis Carrier Status Practice Guidelines: Recommendations of the National Society of Genetic Counselors , 2014, Journal of Genetic Counseling.

[8]  K. Kowdley,et al.  HFE-associated hereditary hemochromatosis , 2009, Genetics in Medicine.

[9]  C. Curry,et al.  ACMG Practice Guideline: lack of evidence for MTHFR polymorphism testing , 2013, Genetics in Medicine.

[10]  B. Pletcher,et al.  Carrier screening in individuals of Ashkenazi Jewish descent , 2008, Genetics in Medicine.

[11]  E. Rossi,et al.  Clinical penetrance of C282Y homozygous HFE haemochromatosis. , 2004, The Clinical biochemist. Reviews.

[12]  Candace Timpte,et al.  The Genetic Information Nondiscrimination Act , 2013 .

[13]  Victoria M. Pratt,et al.  Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel , 2004, Genetics in Medicine.

[14]  G. Annas,et al.  What do Patients Prefer: Informed Consent Models for Genetic Carrier Testing , 2007, Journal of Genetic Counseling.

[15]  B. Yawn,et al.  Screening for Hemochromatosis: Recommendation Statement , 2006, Annals of Internal Medicine.

[16]  T. Prior.  Carrier screening for spinal muscular atrophy , 2008, Genetics in Medicine.

[17]  Quanhe Yang,et al.  5,10-Methylenetetrahydrofolate reductase gene variants and congenital anomalies: a HuGE review. , 2000, American journal of epidemiology.

[18]  J. Metcalfe,et al.  Expanded carrier screening in reproductive healthcare: perspectives from genetics professionals. , 2013, Human reproduction.

[19]  L. Grummer-Strawn,et al.  Prevalence of C282Y and H63D mutations in the hemochromatosis (HFE) gene in the United States. , 2001, JAMA.